» Articles » PMID: 35054798

Radiolabeled Gold Nanoseeds Decorated with Substance P Peptides: Synthesis, Characterization and In Vitro Evaluation in Glioblastoma Cellular Models

Abstract

Despite some progress, the overall survival of patients with glioblastoma (GBM) remains extremely poor. In this context, there is a pressing need to develop innovative therapy strategies for GBM, namely those based on nanomedicine approaches. Towards this goal, we have focused on nanoparticles (AuNP-SP and AuNP-SPTyr8) with a small gold core (ca. 4 nm), carrying DOTA chelators and substance P (SP) peptides. These new SP-containing AuNPs were characterized by a variety of analytical techniques, including TEM and DLS measurements and UV-vis and CD spectroscopy, which proved their high in vitro stability and poor tendency to interact with plasma proteins. Their labeling with diagnostic and therapeutic radionuclides was efficiently performed by DOTA complexation with the trivalent radiometals Ga and Lu or by electrophilic radioiodination with I of the tyrosyl residue in AuNP-SPTyr8. Cellular studies of the resulting radiolabeled AuNPs in NKR1-positive GBM cells (U87, T98G and U373) have shown that the presence of the SP peptides has a crucial and positive impact on their internalization by the tumor cells. Consistently, Lu-AuNP-SPTyr8 showed more pronounced radiobiological effects in U373 cells when compared with the non-targeted congener Lu-AuNP-TDOTA, as assessed by cell viability and clonogenic assays and corroborated by Monte Carlo microdosimetry simulations.

Citing Articles

Preliminary Study on Lutetium-177 and Gold Nanoparticles: Apoptosis and Radiation Enhancement in Hepatic Cancer Cell Line.

Kouri M, Georgopoulos A, Manios G, Maratou E, Spathis A, Chatziioannou S Curr Issues Mol Biol. 2024; 46(11):12244-12259.

PMID: 39590321 PMC: 11592690. DOI: 10.3390/cimb46110727.


Ultrasmall Gold Nanoparticles Radiolabeled with Iodine-125 as Potential New Radiopharmaceutical.

Wang R, Liu H, Antal B, Wolterbeek H, Denkova A ACS Appl Bio Mater. 2024; 7(2):1240-1249.

PMID: 38323544 PMC: 10880057. DOI: 10.1021/acsabm.3c01158.


Carrier systems of radiopharmaceuticals and the application in cancer therapy.

Zhang T, Lei H, Chen X, Dou Z, Yu B, Su W Cell Death Discov. 2024; 10(1):16.

PMID: 38195680 PMC: 10776600. DOI: 10.1038/s41420-023-01778-3.


Methods for Radiolabeling Nanoparticles (Part 3): Therapeutic Use.

Bentivoglio V, Nayak P, Varani M, Lauri C, Signore A Biomolecules. 2023; 13(8).

PMID: 37627307 PMC: 10452659. DOI: 10.3390/biom13081241.


Targeted Glioblastoma Treatment via Synthesis and Functionalization of Gold Nanoparticles With De Novo-Engineered Transferrin-Like Peptides: Protocol for a Novel Method.

Fiedler A, Medeiros M, Fiedler H JMIR Res Protoc. 2023; 12:e49417.

PMID: 37531222 PMC: 10457702. DOI: 10.2196/49417.


References
1.
Schuemann J, Berbeco R, Chithrani D, Cho S, Kumar R, McMahon S . Roadmap to Clinical Use of Gold Nanoparticles for Radiation Sensitization. Int J Radiat Oncol Biol Phys. 2015; 94(1):189-205. PMC: 4692194. DOI: 10.1016/j.ijrobp.2015.09.032. View

2.
Rai Y, Pathak R, Kumari N, Sah D, Pandey S, Kalra N . Mitochondrial biogenesis and metabolic hyperactivation limits the application of MTT assay in the estimation of radiation induced growth inhibition. Sci Rep. 2018; 8(1):1531. PMC: 5784148. DOI: 10.1038/s41598-018-19930-w. View

3.
Krolicki L, Bruchertseifer F, Kunikowska J, Koziara H, Krolicki B, Jakucinski M . Safety and efficacy of targeted alpha therapy with Bi-DOTA-substance P in recurrent glioblastoma. Eur J Nucl Med Mol Imaging. 2018; 46(3):614-622. DOI: 10.1007/s00259-018-4225-7. View

4.
Pellico J, Gawne P, T M de Rosales R . Radiolabelling of nanomaterials for medical imaging and therapy. Chem Soc Rev. 2021; 50(5):3355-3423. DOI: 10.1039/d0cs00384k. View

5.
Vitali M, Casals E, Canals F, Colome N, Puntes V . Simple spectroscopic determination of the hard protein corona composition in AuNPs: albumin at 75. Nanoscale. 2020; 12(29):15832-15844. DOI: 10.1039/d0nr02379e. View